A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-07-22
Target enrollment:
Participant gender:
Summary
This single arm study will assess the effect of tocilizumab + DMARDs (Disease Modifying
Anti-Rheumatic Drugs)on improvement of anemia and fatigue in patients with moderate to severe
active rheumatoid arthritis. Eligible patients who have had an inadequate response to DMARDs
will receive tocilizumab 8mg/kg iv every 4 weeks in combination with standard DMARDs, for 6
months. The anticipated time on study treatment is 3-12 months, and the target sample size is
100-500 individuals.